Allergic rhinitis is a chronic respiratory disease characterized by inflammation of the nasal cavity and affects people of all ages. The main symptoms of allergic rhinitis are sneezing, nasal itching, blocked or runny nose and sore throat. Research suggests that a combination of genetic factors such as family history of allergic rhinitis and environmental factors such as exposure to allergens, including smoke, dust, pollen, insects, molds, or animal dander, may increase the risk for developing allergic rhinitis.

According to GlobalData’s epidemiological forecast, the total prevalent cases of allergic rhinitis in the 7MM will increase from 123,273,876 total prevalent cases in 2013 to 125,427,387 total prevalent cases in 2023, at an annual growth rate of 0.17% during the forecast period.

In 2023, the US will have the highest number of the total prevalent cases of allergic rhinitis with 39,031,365 total prevalent cases, followed by Japan with 36,602,227 total prevalent cases.

To forecast the total prevalent cases of allergic rhinitis in the 7MM, GlobalData epidemiologists selected only nationally representative studies that provided total prevalence of allergic rhinitis using uniform diagnostic criteria based on self-reported prevalence of allergic rhinitis. The use of studies that provided uniform diagnostic criteria for total prevalence of allergic rhinitis facilitated meaningful comparison of the forecast total prevalent cases of allergic rhinitis across the 7MM. Furthermore, GlobalData epidemiologists provided a comprehensive forecast of the total prevalent cases of allergic rhinitis segmented by severity (mild, moderate, and severe) as well as type (seasonal, perennial, and both).

Scope

• The Allergic Rhinitis EpiCast Report provide an overview of the risk factors, comorbidities, and the global and historical trends of allergic rhinitis in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the total prevalent cases of allergic rhinitis segmented by sex and age (ages =18 years).
• The allergic rhinitis epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
• The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

• Develop business strategies by understanding the trends shaping and driving the global allergic rhinitis market.
• Quantify patient populations in the global allergic rhinitis market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for allergic rhinitis therapeutics in each of the markets covered.

Table of Contents

1 Table of Contents 4
1.1 List of Tables5
1.2 List of Figures 6

2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Related Reports 8

3 Epidemiology 9
3.1 Risk Factors and Comorbidities 10
3.1.1 Family history of allergic rhinitis is a strong predictor for allergic rhinitis in children and adults 11
3.1.2 Exposure to allergens in the environment increases the risk for allergic rhinitis 12
3.1.3 Urban living elevates the risk of allergic rhinitis 12
3.1.4 Comorbidities 13
3.2 Global and Historical Trends 14
3.2.1 US 15
3.2.2 5EU 16
3.2.3 Japan 17
3.3 Forecast Methodology 18
3.3.1 Sources Used 20
3.3.2 Sources Not Used 24
3.3.3 Forecast Assumptions and Methods 24
3.4 Epidemiological Forecast of Allergic Rhinitis (2013-2023) 28
3.4.1 Total Prevalent Cases of Allergic Rhinitis 28
3.4.2 Age-Specific Total Prevalent Cases of Allergic Rhinitis 30
3.4.3 Sex-Specific Total Prevalent Cases of Allergic Rhinitis 32
3.4.4 Age-Standardized Total Prevalence of Allergic Rhinitis 34
3.4.5 Distribution of Total Prevalent Cases of Allergic Rhinitis by Severity 35
3.4.6 Distribution of Total Prevalent Cases of Allergic Rhinitis by Type 36
3.4.7 Allergic Rhinitis Total Prevalent Cases Sensitized to Specific Allergens 37
3.5 Discussion 38
3.5.1 Epidemiological Forecast Insight 38
3.5.2 Limitations of the Analysis 39
3.5.3 Strengths of the Analysis 40

4 Appendix 41
4.1 Bibliography 41
4.2 About the Authors 45
4.2.1 Epidemiologists 45
4.2.2 Reviewers 45
4.2.3 Acting Director of Epidemiology 47
4.2.4 Global Head of Healthcare 47
4.3 About GlobalData 48
4.4 About EpiCast 48
4.5 Disclaimer 49

List of Tables

Table 1: Classification of Allergic Rhinitis 10
Table 2: Risk Factors and Comorbidities for Allergic Rhinitis 11
Table 3: Prevalence of Most Frequently Occurring Comorbidities in People with Allergic Rhinitis 14
Table 4: Age-Specific Prevalence of Hay Fever from the NHIS Survey in 2011 16
Table 5: Age- and Sex-Standardized Self-Reported Total Prevalence (%) of Allergic Rhinitis, Ages 20-44 Years, 5EU 16
Table 6: Total Prevalence (%) of Allergic Rhinitis in the EU, Ages 6-14 Years 17
Table 7: 7MM, Sources of Data Used for the Total Prevalence and the Segmentations for Allergic Rhinitis 19
Table 8: 7MM, Sources Excluded for the Epidemiological Forecast of Total Prevalent Cases of Allergic Rhinitis 24
Table 9: 7MM, Total Prevalent Cases of Allergic Rhinitis, Both Sexes, Ages ≥18 Years, N, 2013-2023 29
Table 10: 7MM, Age-Specific Total Prevalent Cases of Allergic Rhinitis, Both Sexes, N (Row %), 2013 31
Table 11: 7MM, Sex-Specific Total Prevalent Cases of Allergic Rhinitis, Ages ≥18 Years, N (Row %), 2013 33
Table 12: 7MM, Distribution of Total Prevalent Cases of Allergic Rhinitis by Severity, Both Sexes, N (Row %), 2013 36
Table 13: 7MM, Distribution of Total Prevalent Cases of Allergic Rhinitis by Type, Both Sexes, N (Row %), 2013 37
Table 14: 7MM, Proportion of Allergic Rhinitis Total Prevalent Cases Sensitized to Specific Allergens, Both Sexes, %, 2013 38

List of Figures

Figure 1: 7MM, Total Prevalent Cases of Allergic Rhinitis, Both Sexes, Ages ≥18 Years, N, 2013-2023 29
Figure 2: 7MM, Age-Specific Total Prevalent Cases of Allergic Rhinitis, Both Sexes, N, 2013 32
Figure 3: 7MM, Sex-Specific Total Prevalent Cases of Allergic Rhinitis, Ages ≥18 Years, N, 2013 34
Figure 4: 7MM, Age-Standardized Total Prevalence (%) of Allergic Rhinitis, Ages ≥18 Years, by Sex, 2013 35